Halozyme Therapeutics (HALO) Receivables - Other (2019 - 2024)
Halozyme Therapeutics (HALO) posted quarterly Receivables - Other of $20.3 million for Q4 2024, up 1930.0% year-over-year from $1.0 million in Q1 2024, and up 1930.0% quarter-over-quarter from $1.0 million in Q4 2023.
Halozyme Therapeutics (HALO) Receivables - Other (2019 - 2024) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Receivables - Other for 6 consecutive years, with $20.3 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Receivables - Other rose 1930.0% year-over-year to $20.3 million; the TTM figure through Dec 2024 stood at $20.3 million (up 1930.0% YoY), while the FY2024 annual figure was $20.3 million, up 1930.0% from the prior year.
- Receivables - Other grew to $20.3 million in Q4 2024 per HALO's latest filing, from $1.0 million in the prior quarter.
- Across five years, Receivables - Other topped out at $69.2 million in Q3 2022 and bottomed at $1.0 million in Q4 2023.
- Historically, Receivables - Other has averaged $23.9 million across 5 years, with a median of $22.4 million in 2023.
- Annual changes were most pronounced in 2023 — Receivables - Other sank 95.23% — and 2024, when it jumped 1930.0%.
- Halozyme Therapeutics' Receivables - Other stood at $7.0 million in 2020, then soared by 328.57% to $30.0 million in 2021, then soared by 130.56% to $69.2 million in 2022, then tumbled by 98.55% to $1.0 million in 2023, then surged by 1930.0% to $20.3 million in 2024.
- Business Quant data shows HALO's Receivables - Other at $20.3 million in Q4 2024, $1.0 million in Q4 2023, and $3.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 20.30 Mn |
| Dec 31, 2024 | 20.30 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Dec 31, 2023 | 1.00 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Sep 30, 2023 | 3.30 Mn |
| Jun 30, 2023 | 24.50 Mn |
| Jun 30, 2023 | 24.50 Mn |
| Mar 31, 2023 | 32.30 Mn |
| Mar 31, 2023 | 32.30 Mn |
| Sep 30, 2022 | 69.17 Mn |
| Sep 30, 2022 | 69.17 Mn |
| Jun 30, 2022 | 19.80 Mn |
| Jun 30, 2022 | 19.80 Mn |
| Mar 31, 2021 | 30.00 Mn |
| Mar 31, 2021 | 30.00 Mn |
| Dec 31, 2020 | 7.00 Mn |
| Dec 31, 2020 | 7.00 Mn |
| Sep 30, 2020 | 32.00 Mn |
| Sep 30, 2020 | 32.00 Mn |